Pro-inflammatory CXCL-10, TNF-α, IL-1β, and IL-6: biomarkers of SARS-CoV-2 infection.
| Title: | Pro-inflammatory CXCL-10, TNF-α, IL-1β, and IL-6: biomarkers of SARS-CoV-2 infection. |
|---|---|
| Authors: | Tripathy AS; Hepatitis Group, ICMR-National Institute of Virology, Pashan, Pune, 411021, Maharashtra, India. anuradhastripathy@hotmail.com.; Vishwakarma S; Hepatitis Group, ICMR-National Institute of Virology, Pashan, Pune, 411021, Maharashtra, India.; Trimbake D; Hepatitis Group, ICMR-National Institute of Virology, Pashan, Pune, 411021, Maharashtra, India.; Gurav YK; Epidemiology Group, ICMR-National Institute of Virology, Pashan, Pune, 411021, Maharashtra, India.; Potdar VA; Influenza Group, ICMR-National Institute of Virology, Pune, 411001, Maharashtra, India.; Mokashi ND; Yashwantrao Chavan Memorial Hospital, Pune, 411018, Maharashtra, India.; Patsute SD; Naidu Hospital, Pune, 411001, Maharashtra, India.; Kaushal H; Influenza Group, ICMR-National Institute of Virology, Pune, 411001, Maharashtra, India.; Choudhary ML; Influenza Group, ICMR-National Institute of Virology, Pune, 411001, Maharashtra, India.; Tilekar BN; Diagnostic Virology Group, ICMR-National Institute of Virology, Pashan, Pune, 411021, Maharashtra, India.; Sarje P; Hepatitis Group, ICMR-National Institute of Virology, Pashan, Pune, 411021, Maharashtra, India.; Dange VS; Pimpri Chinchwad Municipal Corporation, Pimpri, Pune, 411018, Maharashtra, India.; Abraham P; ICMR-National Institute of Virology, Pune, 411001, Maharashtra, India. |
| Source: | Archives of virology [Arch Virol] 2021 Dec; Vol. 166 (12), pp. 3301-3310. Date of Electronic Publication: 2021 Sep 23. |
| Publication Type: | Journal Article |
| Language: | English |
| Journal Info: | Publisher: Springer-Verlag Country of Publication: Austria NLM ID: 7506870 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1432-8798 (Electronic) Linking ISSN: 03048608 NLM ISO Abbreviation: Arch Virol Subsets: MEDLINE |
| Imprint Name(s): | Original Publication: Wien, New York, Springer-Verlag. |
| MeSH Terms: | COVID-19*/diagnosis ; COVID-19*/immunology; Chemokines/*immunology ; Cytokines/*immunology; Biomarkers/blood ; India/epidemiology ; Chemokine CXCL10 ; Humans ; Interleukin-1beta ; Interleukin-6 ; Tumor Necrosis Factor-alpha |
| Abstract: | Currently, the world is witnessing the pandemic of COVID-19, a disease caused by the novel coronavirus SARS-CoV-2. Reported differences in clinical manifestations and outcomes in SARS-CoV-2 infection could be attributed to factors such as virus replication, infiltration of inflammatory cells, and altered cytokine production. Virus-induced aberrant and excessive cytokine production has been linked to the morbidity and mortality of several viral infections. Using a Luminex platform, we investigated plasma cytokine and chemokine levels of 27 analytes from hospitalized asymptomatic (n = 39) and mildly symptomatic (n = 35) SARS-CoV-2-infected patients (in the early phase of infection), recovered individuals (45-60 days postinfection) (n = 40), and uninfected controls (n = 36) from the city of Pune located in the state of Maharashtra in India. Levels of the pro-inflammatory cytokines IL-1β, IL-6, and TNF-α and the chemokine CXCL-10 were significantly higher, while those of the antiviral cytokines IFN-γ and IL-12 p70 were significantly lower in both asymptomatic and mildly symptomatic patients than in controls. Comparison among the patient categories revealed no difference in the levels of the cytokines/chemokines except for CXCL-10 being significantly higher and IL-17, IL-4, and VEGF being significantly lower in the mildly symptomatic patients. Interestingly, levels of all key analytes were significantly lower in recovered individuals than in those in both patient categories. Nevertheless, the level of CXCL10 was significantly higher in the recovered patients than in the controls, indicating that the immune system of SARS-CoV-2 patients may take a longer time to normalize. Our data suggest that IL-6, IL-1β, TNF-α, CXCL-10, and reduced antiviral cytokines could be used as biomarkers of SARS-CoV-2 infection.; (© 2021. The Author(s), under exclusive licence to Springer-Verlag GmbH Austria, part of Springer Nature.) |
| References: | Am J Respir Crit Care Med. 2005 Apr 15;171(8):850-7. (PMID: 15657466); Int J Antimicrob Agents. 2020 May;55(5):105954. (PMID: 32234467); Int Immunol. 2020 Nov 23;32(12):799-804. (PMID: 32645711); Nat Med. 2020 Aug;26(8):1200-1204. (PMID: 32555424); J Viral Hepat. 2011 Oct;18(10):e415-22. (PMID: 21914058); Cell Mol Bioeng. 2020 Jul 27;13(4):259-284. (PMID: 32837585); J Cardiovasc Med (Hagerstown). 2020 Sep;21(9):630-633. (PMID: 32740495); PLoS One. 2010 Oct 01;5(10):. (PMID: 20957032); Lancet Respir Med. 2020 Dec;8(12):1233-1244. (PMID: 33075298); Cytokine Growth Factor Rev. 2020 Jun;53:25-32. (PMID: 32446778); Indian J Med Res. 2020 Feb & Mar;151(2 & 3):255-260. (PMID: 32362650); Clin Exp Immunol. 2004 Apr;136(1):95-103. (PMID: 15030519); Crit Care. 2020 Jun 16;24(1):353. (PMID: 32546188); J Med Virol. 2005 Feb;75(2):185-94. (PMID: 15602737); Indian J Med Res. 2020 May;151(5):486-489. (PMID: 32474556); Emerg Microbes Infect. 2020 Dec;9(1):761-770. (PMID: 32228226); Front Mol Biosci. 2020 Aug 11;7:196. (PMID: 32850977); J Korean Med Sci. 2016 Nov;31(11):1717-1725. (PMID: 27709848); Mol Med. 2020 Oct 29;26(1):97. (PMID: 33121429); J Biol Regul Homeost Agents. 2020 Mar 14;34(2):327-331. (PMID: 32171193); Data Brief. 2020 Jun 30;31:105953. (PMID: 32685628); J Microbiol Immunol Infect. 2020 Jun;53(3):368-370. (PMID: 32205092); Clin Rheumatol. 2020 Jul;39(7):2085-2094. (PMID: 32474885); Cell Host Microbe. 2020 Jun 10;27(6):883-890.e2. (PMID: 32407669); J Autoimmun. 2020 Jul;111:102452. (PMID: 32291137); Cytokine Growth Factor Rev. 2020 Aug;54:62-75. (PMID: 32513566); J Infect Dis. 2020 Aug 4;222(5):746-754. (PMID: 32563194) |
| Substance Nomenclature: | 0 (Biomarkers); 0 (CXCL10 protein, human); 0 (Chemokine CXCL10); 0 (Chemokines); 0 (Cytokines); 0 (IL1B protein, human); 0 (IL6 protein, human); 0 (Interleukin-1beta); 0 (Interleukin-6); 0 (Tumor Necrosis Factor-alpha) |
| Entry Date(s): | Date Created: 20210923 Date Completed: 20211203 Latest Revision: 20220218 |
| Update Code: | 20260130 |
| PubMed Central ID: | PMC8459145 |
| DOI: | 10.1007/s00705-021-05247-z |
| PMID: | 34554303 |
| Database: | MEDLINE |
Journal Article